Last $32.19 USD
Change Today +3.23 / 11.15%
Volume 68.2K
PRTK On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GM
As of 3:46 PM 12/17/14 All times are local (Market data is delayed by at least 15 minutes).

paratek pharmaceuticals inc (PRTK) Snapshot

Open
$30.56
Previous Close
$28.96
Day High
$32.19
Day Low
$29.80
52 Week High
12/17/14 - $32.19
52 Week Low
10/24/14 - $11.30
Market Cap
464.1M
Average Volume 10 Days
40.0K
EPS TTM
$-12.31
Shares Outstanding
14.4M
EX-Date
10/31/14
P/E TM
--
Dividend
--
Dividend Yield
74.46%
Current Stock Chart for PARATEK PHARMACEUTICALS INC (PRTK)

paratek pharmaceuticals inc (PRTK) Related Bloomberg News

View More Bloomberg News

paratek pharmaceuticals inc (PRTK) Related Businessweek News

No Related Businessweek News Found

paratek pharmaceuticals inc (PRTK) Details

Paratek Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines to save lives and alleviate suffering. Its lead product candidate, omadacycline, is a tetracycline-derived, broad-spectrum antibiotic being developed in oral tablet and intravenous formulations for use as a monotherapy antibiotic for bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections, and other serious community-acquired bacterial infections. The company has special protocol assessment agreements with The Food and Drug Administration (FDA) for the Phase III trials planned in ABSSSI and CABP. Its other product candidate, WC 3035 (sarecycline), is a new tetracycline-derived compound, with dual narrow-spectrum antibacterial and potent anti-inflammatory activity for the treatment of acne and rosacea in the community setting. The company has licensed rights of WC 3035 to Actavis, which has completed Phase II clinical trials for the treatment of acne and rosacea in the United States. Paratek Pharmaceuticals, Inc. is based in Boston, Massachusetts.

11 Employees
Last Reported Date: 10/2/14

paratek pharmaceuticals inc (PRTK) Top Compensated Officers

President, Chief Medical Officer and Director
Total Annual Compensation: $291.1K
Interim Chief Financial Officer, Vice Preside...
Total Annual Compensation: $216.0K
Chief Compliance Officer, Vice President of A...
Total Annual Compensation: $265.9K
Vice President of Research and Development
Total Annual Compensation: $226.0K
Compensation as of Fiscal Year 2013.

paratek pharmaceuticals inc (PRTK) Key Developments

Paratek Pharmaceuticals, Inc. Announces Chief Financial Officer Changes, Effective December 18, 2014

Paratek Pharmaceuticals, Inc. announced Douglas Pagán will join Paratek's executive leadership team as Chief Financial Officer, effective December 18, 2014. Mr. Pagán will report to Michael F. Bigham, Chairman and Chief Executive Officer of Paratek. Mr. Pagán will succeed Kathryn Boxmeyer, Paratek's current interim CFO, who is stepping down to pursue other opportunities.

Paratek Pharmaceuticals, Inc. Approves the Dismissal of Ernst & Young LLP as Independent Registered Public Accounting Firm

On November 12, 2014, the Audit Committee of the Board of Directors of Paratek Pharmaceuticals, Inc. approved the dismissal of Ernst & Young LLP as the company’s independent registered public accounting firm, effective immediately.

Paratek Pharmaceuticals Announces Newly Expanded Board of Directors

Paratek Pharmaceuticals, Inc. recently announced the members of its newly expanded board of directors. Michael F Bigham, Thomas J. Dietz, Ph.D, Robert Radie, Jeffrey Stein, Ph.D., Richard Lim, and Evan Loh M.D. Michael F. Bigham, appointed Chief Executive Officer and Chairman of the board of directors of Paratek in June 2014. Mr. Bigham has more than 25 years of senior leadership experience in the biopharmaceutical industry. Since 2003, he has been a Partner at Abingworth LLP. He currently serves on the boards of Avedro and Secure EDI, where he is Chairman, and has held several directorships, including at Avila Therapeutics (where he was also the founding Chairman and CEO), Magellan Biosciences, Portola Pharmaceuticals, Supernus Pharmaceuticals and Valeritas. Mr. Bigham was formerly Vice Chairman of Corixa Corporation, and was President and Chief Executive of Coulter Pharmaceuticals, until it merged into Corixa. Previously, he was an early employee at Gilead Sciences where he served in various capacities, including Executive Vice President of Operations and Chief Financial Officer. Thomas J. Dietz, Ph.D., was a member of Transcept's board of directors since his appointment in April 2013. Dr. Dietz has served as Chairman and CEO of Waypoint Holdings, LLC, since December 2010. He was previously co-CEO and then CEO and a director of Pacific Growth Equities, LLC. Robert Radie, has been President and Chief Executive Officer of Egalet since March 2012. From November 2010 to October 2011, Mr. Radie served as President and Chief Executive Officer of Topaz Pharmaceuticals Inc. Jeffrey Stein, Ph.D., has been President and Chief Executive Officer of Cidara Therapeutics since 2014. Prior to joining Cidara, Dr. Stein was Chief Executive Officer of Trius Therapeutics from its founding in 2007 until its acquisition by Cubist Pharmaceuticals in September of 2013. Dr. Stein is also founding Chairman and President of the Antibiotics Working Group. Previously, Dr. Stein was a Venture Partner and Kauffman Fellow with Sofinnova Ventures and opened the firm's San Diego office in 2005. Richard Lim has been a member of Paratek's board of directors since March 2014. Mr. Lim is a General Partner at Omega Funds and has over 20 years in principal investment and strategic consulting, all within life science and healthcare. He was previously a General Partner at MVM Life Science Partners. He was previously a Vice President at Saunders, Karp & Megrue (SKM), where he specialized in healthcare growth capital and leveraged transactions. Evan Loh, MD, was elected President of Paratek in June 2014. He was appointed Chief Medical Officer of Paratek in June 2012 and has served on Paratek's board of directors since May 2012, including Chairman from June 2012 until June 2014. From October 2009 to January 2012, Dr. Loh served as Senior Vice President, Development and Strategic Operations, Worldwide Research and Development, at Pfizer. While at Pfizer, Dr. Loh's responsibilities included scientific, operational, and strategic drug development oversight for all pre-proof of concept development phase programs and leading portfolio prioritization.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PRTK:US $32.19 USD +3.23

PRTK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PRTK.
View Industry Companies
 

Industry Analysis

PRTK

Industry Average

Valuation PRTK Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 52.0x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 530.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PARATEK PHARMACEUTICALS INC, please visit www.paratekpharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.